StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

Analysts at StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of IRIDEX stock opened at $1.63 on Friday. The firm has a market cap of $27.17 million, a PE ratio of -2.44 and a beta of 0.82. IRIDEX has a twelve month low of $1.27 and a twelve month high of $3.65. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average price of $1.70 and a 200 day moving average price of $1.81.

IRIDEX (NASDAQ:IRIX) last posted its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The business had revenue of $11.58 million during the quarter. During the same period in the previous year, the business earned ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.